IV 

111TH CONGRESS 

1ST SESSION H. RES. 366 

Recognizing the 40th anniversary of the National Eye Institute (NEI) and 

expressing support for designation of 2010 through 2020 as the ‘‘Decade 

of Vision’’. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 27, 2009 

Ms. BALDWIN (for herself, Mr. SESSIONS, Mr. ALTMIRE, Mr. KIND, Mr. 

COBLE, Mr. GRAYSON, Mr. TERRY, Mr. MCCOTTER, Mr. BOOZMAN, Mr. 

MORAN of Virginia, Mr. GENE GREEN of Texas, Mr. MARCHANT, Mr. 

ISRAEL, Mr. KAGEN, Mr. KING of New York, Mr. PETRI, Mr. HINOJOSA, 

Ms. BORDALLO, Mr. HASTINGS of Florida, and Mr. SERRANO) submitted 

the following resolution; which was referred to the Committee on Energy 

and Commerce 

RESOLUTION 

Recognizing the 40th anniversary of the National Eye Institute (NEI) and expressing support for designation of 

2010 through 2020 as the ‘‘Decade of Vision’’. 

Whereas vision impairment and eye disease is a major public 

health problem, especially due to the aging of the population, a disproportionate incidence of eye disease in minority populations, and vision loss as a result of diabetes 

and other chronic diseases, which costs the Nation 

$68,000,000,000 annually in health care costs, lost productivity, reduced independence, diminished quality of 

life, increased depression, and accelerated mortality; 


wwoods2 on PRODPC68 with BILLS
2 

•HRES 366 IH 

Whereas 38,000,000 people in the United States age 40-plus 

currently experience blindness, low-vision, or an age-related eye disease, and this number is expected to grow to 

50,000,000 by 2020, a year mid-way in the tidal wave of 

78,000,000 baby boomers who will begin turning age 65 

in 2010, and many of whom will continue working well 

beyond age 65; 

Whereas, in public opinion polls over the past 40 years, people in the United States have consistently identified fear 

of vision loss as second only to fear of cancer and, as recently as a 2008 NEI study, 71 percent of respondents 

indicated that a loss of their eyesight would have the 

greatest impact on their life; 

Whereas, with wisdom and foresight, Congress passed the 

National Eye Institute (NEI) Act (Public Law 90–489), 

which was signed into law by President Johnson on August 16, 1968, with the NEI holding the first meeting of 

its National Advisory Eye Council (NAEC) on April 3, 

1969; 

Whereas the NEI leads the Nation’s Federal commitment to 

basic and clinical research, research training, and other 

programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of 

sight and the special health problems and needs of individuals who are visually-impaired or blind, and to disseminate information aimed at the prevention of blindness, specifically with public and professional education 

facilitated through its National Eye Health Education 

Program (NEHEP); 

Whereas the NEI maximizes Federal funding by devoting 85 

percent of its budget to extramural research that addresses the breadth of eye and vision disorders, including 


wwoods2 on PRODPC68 with BILLS
3 

•HRES 366 IH 

‘‘back of the eye’’ retinal and optic nerve disease, such 

as age-related macular degeneration (AMD), glaucoma, 

and diabetic retinopathy, and concomitant low vision, and 

‘‘front of the eye’’ disease, including corneal, lens, cataract, and refractive errors; 

Whereas the NEI research benefits children, including premature infants born with retinopathy and school children 

with amblyopia (‘‘lazy eye’’); 

Whereas the NEI benefits older citizens in the United States 

by predicting, preventing, and preempting aging eye disease, thereby enabling more productive lives and reducing 

Medicare costs; 

Whereas the NEI has been a leader in basic research, working with the NIH’s Human Genome Project to translate 

discoveries of genes related to eye disease and vision impairment, which comprises one quarter of genes discovered to date, into diagnostic and treatment modalities; 

Whereas the NEI has been a leader in clinical research, funding more than 60 clinical trials, including a series of Diabetic Retinopathy Clinical Trials Networks, in association 

with the National Institute for Diabetes and Digestive 

and Kidney Disorders (NIDDK), which have developed 

treatment strategies that have been determined by the 

NEI to be 90 percent effective and save an estimated 

$1,600,000,000 per year in blindness and vision impairment disability costs; 

Whereas the NEI has been a leader in prevention research, 

having reported from the first phase of its Age-Related 

Eye Disease Study (AREDS) that high levels of dietary 

zinc and anti-oxidant vitamins reduced vision loss in individuals at high risk for developing advanced AMD by a 


wwoods2 on PRODPC68 with BILLS
4 

•HRES 366 IH 

magnitude of 25 percent, and in its second phase, is now 

studying the impact of other nutritional supplements; 

Whereas the NEI has been a leader in epidemiologic research, identifying the basis and progression of eye disease and its disproportionate incidence in minority populations such that informed public health policy decisions 

can be made regarding prevention, early diagnosis, and 

treatment; 

Whereas the NEI has been a leader in collaborative, transNIH Institute research, working with the National Cancer Institute (NCI) and the National Heart, Lung, and 

Blood Institute (NHLBI) on factors that promote or inhibit new blood vessel growth that has resulted in the 

first generation of Food and Drug Administration 

(FDA)-approved ophthalmic drugs to inhibit abnormal 

blood vessel growth in the ‘‘wet’’ form of AMD, thereby 

stabilizing and often restoring vision; 

Whereas the NEI has been a leader in collaborative research 

with other Federal entities, such that its bioengineering 

research partnership with the National Science Foundation and the Department of Energy has resulted in a retinal chip implant, referred to as the ‘‘Bionic Eye’’, that 

has enabled individuals who have been blind for decades 

to perceive visual images; 

Whereas the NEI has been a leader in collaborative research 

with private funding entities, such that its human gene 

therapy trial with the Foundation Fighting Blindness for 

individuals with Leber Congenital Amaurosis (LCA), a 

rapid retinal degeneration that blinds infants in their 

first year of life, has demonstrated measurable vision improvement even within the initial safety trials; 


wwoods2 on PRODPC68 with BILLS
5 

•HRES 366 IH 

Whereas in the decade 2010 through 2020, the Nation will 

face unprecedented public health challenges associated 

with aging, health disparities, and chronic disease; and 

Whereas Federal support at the NEI and related Department 

of Health and Human Services agencies is essential for 

the prevention and early detection, access to treatment 

and rehabilitation, and research associated with vision 

impairment and eye disease: Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) recognizes the 40th anniversary of the Na3 tional Eye Institute (NEI), commends it for its lead4 ership, and supports its mission to prevent blindness 

5 and to save and restore vision; 

6 (2) supports the designation of the ‘‘Decade of 

7 Vision’’ to maintain a sustained awareness in the 

8 next decade of the unprecedented public health chal9 lenges associated with vision impairment and eye 

10 disease and to emphasize the need for Federal sup11 port for prevention and early detection, access to 

12 treatment and rehabilitation, and research; and 

13 (3) commends the National Alliance for Eye 

14 and Vision Research (NAEVR), which serves as the 

15 ‘‘Friends of the National Eye Institute’’, for its ef16 forts to expand awareness of the incidence and eco17 nomic burden of eye disease through its Decade of 

18 Vision 2010–2020 Initiative. 

Æ 


wwoods2 on PRODPC68 with BILLS